N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

Trial Profile

N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia

Phase of Trial: Phase II/III

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Carglumic acid (Primary)
  • Indications Hyperammonaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2015 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018 as reported by ClinicalTrials.gov record.
    • 11 Dec 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2017 as reported by clinicalTrials.gov record.
    • 13 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top